GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

For advertisers already supporting college sports, the ability to sponsor an athlete directly adds significant authenticity ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

We list the best Adobe Sign alternative, to make it simple and easy to sign digital documents without having to subscribe to Adobe Document Cloud. Finding the best Adobe Sign alternatives is ...

2.1 UK Honours degree or equivalent. Applications from candidates with academic backgrounds in Marketing, Management, Business, Arts, Fashion and Social Science (combinations of English, History, ...

After hours: September 20 at 7:44 PM EDT Loading Chart for GSK ...

A recent study estimates the prevalence of primary care and emergency department visits by young children to treat respiratory syncytial virus (RSV), finding that the rates vary widely by country.